0001040368-18-000002.txt : 20180904 0001040368-18-000002.hdr.sgml : 20180904 20180904140800 ACCESSION NUMBER: 0001040368-18-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180904 DATE AS OF CHANGE: 20180904 EFFECTIVENESS DATE: 20180904 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Advanced Proteome Therapeutics CORP CENTRAL INDEX KEY: 0001040368 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-320578 FILM NUMBER: 181052038 BUSINESS ADDRESS: STREET 1: BIOSQUARE, 650 ALBANY STREET STREET 2: SUITE 113 CITY: BOSTON STATE: MA ZIP: 02118 BUSINESS PHONE: 617-638-0340 MAIL ADDRESS: STREET 1: BIOSQUARE, 650 ALBANY STREET STREET 2: SUITE 113 CITY: BOSTON STATE: MA ZIP: 02118 FORMER COMPANY: FORMER CONFORMED NAME: THRILLTIME ENTERTAINMENT INTERNATIONAL INC DATE OF NAME CHANGE: 19970903 FORMER COMPANY: FORMER CONFORMED NAME: NEWERA CAPITAL CORP DATE OF NAME CHANGE: 19970603 D 1 primary_doc.xml X0708 D LIVE 0001040368 Advanced Proteome Therapeutics CORP BIOSQUARE, 650 ALBANY STREET SUITE 113 BOSTON MA MASSACHUSETTS 02118 617-638-0340 BRITISH COLUMBIA, CANADA THRILLTIME ENTERTAINMENT INTERNATIONAL INC NEWERA CAPITAL CORP Corporation true William John (Bill) Dickie 804-750 West Pender Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 2T7 Executive Officer Director President and CEO Alexander (Allen) Krantz 804-750 West Pender Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 2T7 Executive Officer Director COO, CSO and Secretary Ken Phillippe 804-750 West Pender Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 2T7 Executive Officer CFO Paul Woodward 804-750 West Pender Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 2T7 Director John Garrett 804-750 West Pender Street Vancouver A1 BRITISH COLUMBIA, CANADA V6C 2T7 Director Biotechnology No Revenues 06b false 2018-08-22 false true true true true Each unit consists of 1 common share and 1 transferable share purchase warrant. Each warrant is exercisable at a price of CAD$0.075 per share for 2 years. false 0 38414 15365 23049 The additional USD$23,048.56 may be received upon the exercise of share purchase warrants sold inside and outside the U.S. US dollar amounts are based on the Bank of Canada noon rate of exchange on Aug. 22/18, CAD$1.3016 = US$1. false 1 0 0 0 false Advanced Proteome Therapeutics CORP /s/ William John (Bill) Dickie William John (Bill) Dickie CEO 2018-09-04